Rezolute reports Q2 FY2024 net loss $13.9M; initiates Phase 3 for RZ358 in cHI

Rezolute, Inc.

2024-Q2 EPS reported -$0.55

Net loss of $13.9M for Q2 FY2024, compared to $13.6M same period prior year.
Cash, cash equivalents and investments $96.0M as of Dec 31, 2023, down from $118.4M at June 30, 2023.
Initiated sunRIZE Phase 3 study of RZ358 in congenital hyperinsulinism; topline results expected mid-2025.
Completed enrollment in Phase 2 study of RZ402 for diabetic macular edema; topline data expected Q2 2024.
Appointed Daron Evans as CFO, expanding leadership for late-stage development.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Rezolute, Inc. reported second quarter of fiscal 2024 ended December 31, 2023 results: net income $13.9 million.

Period: second quarter of fiscal 2024 ended December 31, 2023
Net income: $13.9 million
Result: reported results

Exact text from the filing

Net loss was $13.9 million for the second quarter of fiscal 2024, compared to $13.6 million for the same period in fiscal 2023

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Rezolute, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-24-019884

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.